Former Pfizer VP: COVID vaccines pose ‘severe risk’ of infertility for women

Share:

(LifeSiteNews) – Scientists have known for nearly a decade that the lipid nanoparticles like those currently used in novel mRNA COVID vaccines accumulate in ovaries and are potentially toxic to reproductive health, a former vice president and top researcher at Pfizer said at a conference hosted by LifeSiteNews Thursday on the fertility dangers of COVID vaccines.

“You’re not being told the truth,” said Michael Yeadon, former Pfizer Vice President and Chief Scientist Worldwide for Respiratory Pharmacology and Toxicology, who is now the Chief Scientific Advisor for the Truth for Health Foundation. “Thinking about this, I try to imagine that I was speaking to my own young adult daughters, for whom I would be very concerned if they got these vaccines.” 

Yeadon cited scientific papers dating back to 2012 that warn of potential reproductive hazards of lipid nanoparticles that are used in COVID shots.

Both Moderna’s and Pfizer’s mRNA vaccines use specialized nanoparticle lipids or lipoproteins as carriers for their main ingredient – unstable mRNA protein that causes cells to produce the notorious coronavirus spike protein and elicit an immune response. These are the molecules that required the extremely low temperatures to preserve stability of the lipid encasing the fragile mRNA.

Accumulation in reproductive organs

German researchers reported in their paper published nine years ago, “Accumulation of nanocarriers in the ovary: A neglected toxicity risk?,” that there is a “potential toxicity risk of all nanoscaled drug delivery systems” and an accumulation of different microscopic carrier molecules in rodent ovaries. Their research involved injection of lipid “nanocarriers,” including some with an ingredient common to both Pfizer’s and Moderna’s mRNA COVID vaccines: polyethylene glycol. 

Instead of loading the carriers with drugs or mRNA, the researchers from Martin Luther University Halle-Wittenberg Department of Pharmaceutical Technology and Biopharmaceutics and the University of Regensburg loaded the nanocarriers with a fluorescent dye they could trace. They reported a “high local accumulation of nanoparticles” in “specific locations of the ovaries” in all mice and rats treated with five different nanocarrier drug delivery systems of different sizes.

Remained in ovaries 25 days later

The fluorescence intensity was detectable in ovaries just two hours after injection and increased within ovaries after 24 hours and remained constant at a high level over several days. A bright fluorescence signal was detectable even 25 days after injection, they reported.

The German researchers warned that this accumulation in ovaries may alert to an “important toxicity issue in humans,” but they did not know. Perhaps, it “might as well open a new field of targeted ovarian therapies,” they reported and concluded that further study was necessary to discover the unknown impact of the phenomenon.